Dermapharm Holding stock has been grinding lower for months, yet today’s reaction hinges on a very simple question: Do you think the profit squeeze in this quarter is a blip or the start of a trend? Revenue in Q2 came in at €315.8m, while basic earnings per share landed at €0.47, well below the €0.84 booked in Q1.

The one year picture still shows earnings growth and a net margin of 12.1%. The market is weighing that against a higher debt load and asking whether this richer margin base is resilient enough to justify any patience.

Is Dermapharm Holding now a clear bargain on 13.5x trailing P/E, or just cheap for a reason given the debt load and recent earnings squeeze? Compare the current share price against our valuation analysis…